TD Cowen analyst Marc Frahm has maintained their bullish stance on RVMD stock, giving a Buy rating yesterday.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Marc Frahm has given his Buy rating due to a combination of factors that highlight Revolution Medicines’ strategic advancements in pancreatic ductal adenocarcinoma (PDAC) treatment. The company is making significant progress with its daraxonrasib trials, including the RASolute302, which is nearing enrollment completion, and the initiation of RASolute303 and RASolute304 trials. These efforts are aimed at establishing daraxonrasib as a global standard of care across various PDAC lines, offering a substantial market opportunity.
Additionally, Revolution Medicines is exploring further potential with zoldonrasib, particularly in first-line G12D+ PDAC, with plans for a pivotal trial in 2026. Despite emerging competition, the management’s confidence in zoldonrasib’s leading position among G12D specific agents reinforces the company’s robust pipeline. These developments, along with the company’s strong financial position, underpin Frahm’s optimistic outlook and Buy rating for Revolution Medicines.
In another report released yesterday, LifeSci Capital also reiterated a Buy rating on the stock with a $104.00 price target.